```html

Trousseau Syndrome – Comprehensive Medical Guide

Overview

Trousseau syndrome, also called cancer‑associated hypercoagulability or migratory thrombophlebitis, is a paraneoplastic condition in which cancer triggers abnormal clotting in the veins and arteries. The syndrome can present as recurrent, unexplained blood clots (deep‑vein thrombosis, pulmonary embolism, arterial occlusions) that often appear before the underlying malignancy is diagnosed.

Who it affects: It most commonly occurs in adults over 50 years old with solid‑organ cancers, particularly adenocarcinomas of the pancreas, lung, stomach, ovary, and prostate. However, any malignant tumor that releases pro‑coagulant substances can provoke the syndrome.

Prevalence: The exact prevalence is difficult to determine because many cases are diagnosed only after a clot leads to a cancer work‑up. Studies estimate that 5–10 % of patients with pancreatic cancer and up to 20 % of patients with lung adenocarcinoma develop Trousseau‑type hypercoagulability [1] Mayo Clinic; [2] National Cancer Institute].

Symptoms

Symptoms are related to the location of the clot and may be intermittent or recurrent.

• Unexplained deep‑vein thrombosis (DVT) – swelling, pain, warmth, and redness in the leg or arm.
• Pulmonary embolism (PE) – sudden shortness of breath, chest pain that worsens with breathing, rapid heart rate, or fainting.
• Migratory thrombophlebitis – painful, inflamed veins that appear in different locations over weeks to months.
• Arterial thrombotic events – stroke‑like symptoms (weakness, speech difficulty), transient ischemic attacks, or limb ischemia (pain, pallor, coldness).
• Skin manifestations – livedo reticularis (net‑like mottling), purpura, or digital (finger/toe) gangrene.
• Systemic signs – unexplained weight loss, fatigue, low‑grade fever, or night sweats, often signaling an underlying malignancy.

Causes and Risk Factors

Pathophysiology

Cancer cells can produce several pro‑coagulant factors that disturb the delicate balance of the clotting cascade:

• Tissue factor (TF) – a membrane protein that initiates the extrinsic coagulation pathway.
• Mucins – high‑molecular‑weight glycoproteins released by adenocarcinomas that interact with selectins on platelets and endothelial cells, promoting aggregation.
• Cytokines (e.g., interleukin‑1, tumor necrosis factor‑α) – stimulate endothelial cells to express adhesion molecules and amplify clot formation.
• Microparticles and extracellular vesicles – carry TF and other clotting proteins in the bloodstream.

Risk Factors

• Diagnosis of an active solid tumor, especially pancreatic (≈85 % of cases), lung, gastric, ovarian, or prostate adenocarcinoma.
• Metastatic disease or high tumor burden.
• Previous thrombotic events.
• Use of central venous catheters, chemotherapy agents (e.g., platinum compounds, thalidomide, lenalidomide), or hormonal therapy.
• Traditional VTE risk factors (obesity, immobility, smoking, inherited thrombophilia) that compound the cancer‑related risk.

Diagnosis

Because Trousseau syndrome is a diagnosis of exclusion, clinicians follow a systematic approach:

Clinical assessment

• Detailed history of clot events, cancer diagnosis, medication use, and family history of clotting disorders.
• Physical examination focused on signs of DVT, PE, arterial occlusion, and skin changes.

Laboratory tests

• Complete blood count (CBC) – may show anemia of chronic disease.
• Coagulation panel: PT/INR, aPTT, fibrinogen, D‑dimer (often markedly elevated).
• Serum tumor markers (CA 19‑9, CEA, AFP) if a specific cancer is suspected.
• Thrombophilia work‑up (protein C/S, antithrombin III, factor V Leiden) if no cancer is found after initial evaluation.

Imaging studies

• Duplex ultrasonography – first‑line for DVT.
• CT pulmonary angiography (CTPA) – detects pulmonary emboli.
• Magnetic resonance angiography (MRA) or CT angiography – evaluates arterial thrombosis.
• Whole‑body PET/CT or contrast‑enhanced CT – helps locate occult malignancy when clot is the presenting sign.

Diagnostic criteria (simplified)

1. Unexplained venous or arterial thrombosis (often recurrent or migratory).
2. Exclusion of other causes (e.g., trauma, infection, primary thrombophilia).
3. Presence of an active cancer or discovery of a malignancy within 12 months of the thrombotic event.

Treatment Options

Management focuses on two fronts: treating the underlying cancer and controlling the hypercoagulable state.

Anticoagulation

• Low‑molecular‑weight heparin (LMWH) – First‑line for cancer‑associated thrombosis (e.g., enoxaparin 1 mg/kg BID). Studies show lower recurrence than warfarin [3] CLOT trial, NEJM 2003.
• Direct oral anticoagulants (DOACs) – Apixaban, rivaroxaban, or edoxaban are increasingly used; they have comparable efficacy but slightly higher bleeding risk in GI cancers [4] Hokusai‑VTE Cancer trial, Lancet 2018.
• Therapy is usually continued for at least 6 months and often indefinitely as long as the malignancy remains active.

Targeted cancer therapy

Effective tumor control reduces pro‑coagulant stimulus. Options include surgery, radiation, chemotherapy, immunotherapy, or targeted agents according to tumor type and stage.

Adjunctive measures

• Compression stockings for lower‑extremity DVT prophylaxis.
• Mechanical prophylaxis (intermittent pneumatic compression) during hospital stays.
• Management of reversible risk factors – smoking cessation, weight reduction, ambulation.

When anticoagulation is contraindicated

In rare cases of severe bleeding risk, an inferior vena cava (IVC) filter may be placed temporarily, but long‑term filter use is discouraged because of thrombosis risk.

Living with Trousseau Syndrome

Medication adherence

• Take anticoagulants exactly as prescribed; missed doses can rapidly increase clot risk.
• Monitor for signs of bleeding (gums, bruising, dark stools) and report promptly.

Regular follow‑up

• Oncologic appointments to assess tumor response.
• Hematology or vascular clinic visits every 3–6 months for coagulation monitoring.

Lifestyle tips

• Stay active – aim for at least 150 minutes of moderate‑intensity aerobic activity per week, unless limited by symptoms.
• Maintain a healthy weight (BMI < 25 kg/m²) to lower VTE risk.
• Hydrate well; dehydration can increase blood viscosity.
• Avoid prolonged immobilization (e.g., long flights); consider prophylactic LMWH if travel >4 hours.
• Discuss any new medications (including over‑the‑counter NSAIDs) with your doctor because they can interact with anticoagulants.

Prevention

While the underlying cancer cannot always be prevented, steps can be taken to mitigate clot risk:

• Early cancer detection – routine screenings (colonoscopy, low‑dose CT for high‑risk smokers, mammography) can catch malignancies before they become advanced.
• Prophylactic anticoagulation – recommended for hospitalized cancer patients and those undergoing major surgery.
• Control modifiable VTE risk factors – stop smoking, limit alcohol, manage diabetes and hypertension.
• Educate caregivers – ensure everyone knows the signs of clotting and bleeding.

Complications

If left untreated, Trousseau syndrome can lead to life‑threatening events:

• Recurrent pulmonary embolism → right‑heart strain, cardiac arrest.
• Extensive DVT → post‑thrombotic syndrome (chronic pain, swelling, ulceration).
• Arterial occlusion → stroke, myocardial infarction, limb loss.
• Bleeding from anticoagulation therapy, especially if dosing is not carefully monitored.
• Worsening of cancer prognosis – studies show a 30 % increase in mortality when cancer‑associated thrombosis occurs [5] Khorana et al., JCO 2013.

When to Seek Emergency Care

References

1. Mayo Clinic. “Trousseau syndrome.” Updated 2023. mayoclinic.org.
2. National Cancer Institute. “Hypercoagulability and Cancer.” 2022. cancer.gov.
3. Liu et al. “Low‑Molecular‑Weight Heparin versus Warfarin for Cancer‑Associated Thrombosis (CLOT Study).” New England Journal of Medicine, 2003.
4. Raskob GE, et al. “Edoxaban for Cancer‑Associated Venous Thromboembolism.” Lancet, 2018.
5. Khorana AA, et al. “Impact of Cancer‑Associated Thrombosis on Mortality.” Journal of Clinical Oncology, 2013.

```